Atreca, Inc. (NASDAQ:BCEL) insider Tito Serafini sold 10,000 shares of the stock in a transaction that occurred on Monday, January 11th. The stock was sold at an average price of $15.02, for a total value of $150,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Tito Serafini also recently made the following trade(s):
- On Friday, December 11th, Tito Serafini sold 10,000 shares of Atreca stock. The stock was sold at an average price of $15.87, for a total value of $158,700.00.
- On Monday, November 16th, Tito Serafini sold 8,847 shares of Atreca stock. The stock was sold at an average price of $15.12, for a total value of $133,766.64.
Shares of BCEL opened at $14.77 on Thursday. The stock has a 50 day moving average of $15.71 and a 200 day moving average of $15.11. Atreca, Inc. has a 12 month low of $10.88 and a 12 month high of $29.35. The company has a market capitalization of $542.16 million, a price-to-earnings ratio of -5.24 and a beta of 0.08.
Large investors have recently added to or reduced their stakes in the business. Bank of Montreal Can purchased a new stake in Atreca in the second quarter worth $34,000. Great West Life Assurance Co. Can purchased a new stake in Atreca in the second quarter worth $41,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Atreca in the third quarter worth $40,000. BNP Paribas Arbitrage SA increased its position in Atreca by 723.4% in the third quarter. BNP Paribas Arbitrage SA now owns 6,966 shares of the company’s stock worth $97,000 after buying an additional 6,120 shares during the last quarter. Finally, Exane Derivatives increased its position in Atreca by 88.9% in the third quarter. Exane Derivatives now owns 8,068 shares of the company’s stock worth $113,000 after buying an additional 3,798 shares during the last quarter. 69.64% of the stock is owned by institutional investors and hedge funds.
Several brokerages have recently commented on BCEL. BidaskClub downgraded Atreca from a “sell” rating to a “strong sell” rating in a research note on Wednesday, December 30th. Zacks Investment Research downgraded Atreca from a “buy” rating to a “hold” rating in a research report on Friday, October 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $26.40.
Atreca, Inc, a biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody in clinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Read More: Why do earnings reports matter?
Receive News & Ratings for Atreca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atreca and related companies with MarketBeat.com's FREE daily email newsletter.